In conclusion, tenecteplase , which can be administered more rapidly than alteplase before thrombectomy in patients with ischemic stroke , was noninferior to alteplase in restoring perfusion in the territory of a proximal cerebral-artery occlusion. Listing a study does not mean it has been evaluated by the U. This study confirms the efficacy and safety of tenecteplase for stroke thrombolysis in our clinical setting. SICH, whereas no difference was found between doses of 0. Most patients enrolled in this study had mild stroke. Tenecteplase was not superior to alteplase and showed a similar safety profile.

Further trials are needed to establish the safety and efficacy in patients with severe stroke and whether tenecteplase is non-inferior to alteplase. Finally, a recent meta-analysis pointed out that tenecteplase is not inferior to alteplase in reducing days disability among stroke patients 10. Intravenous alteplase is the only approved treatment for acute ischemic stroke. How does a hemorrhagic stroke differ from an ischemic stroke?
It also is used to treat patients before. In a recent trial, treatment with tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase if administered to patients with ischemic stroke within 4.